Author

A. B. Vogel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:clinical cohort / trial· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Muik· 3 shared A. Gueler· 2 shared A.-K. Wallisch· 2 shared B. G. Lui· 2 shared H. Cai· 2 shared K. A. Swanson· 2 shared K. C. Walzer· 2 shared M. S. Maddur· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Muik

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

K. Modjarrad, Y. Che, W. Chen, H. Wu, C. I. Cadima, A. Muik, M. S. Maddur, K. R. Tompkins, L. T. Martinez, H. Cai, M. Hong, S. Mensah, B. Cumbia, L. Falcao, J. S. Chang, , K. Swanson

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

bioRxiv · Nov 17, 2023Immunology

Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice

A. Muik, B. G. Lui, M. Bacher, A.-K. Wallisch, A. Toker, C. I. C. Couto, A. Gueler, V. Mampilli, G. J. Schmitt, J. Mottl, T. Ziegenhals, S. Fesser, J. Reinholz, F. Wernig, K.-G. Schraut, , U. Sahin

This study shows that exposure to BA.4/BA.5 spike glycoprotein enhances neutralizing antibody breadth against Omicron variants in vaccinated humans and mice.

bioRxiv · Sep 21, 2022 · PreprintImmunology

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. Gueler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, , M. R Gutman

This paper evaluates two BNT162b vaccine candidates in non-human primates, showing they are immunogenic and protect against SARS-CoV-2 infection.

bioRxiv · Dec 11, 2020 · PreprintImmunology